processa pharmaceuticals was founded in october 2017 with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. the company is headquartered in hanover, maryland.
Company profile
Ticker
PCSA
Exchange
Website
CEO
David Young
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Heatwurx, Inc.
SEC CIK
Corporate docs
Subsidiaries
Processa Therapeutics LLC ...
PCSA stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
17 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer
8 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
29 Jun 23
8-K
Regulation FD Disclosure
21 Jun 23
8-K
Regulation FD Disclosure
24 May 23
8-K
Regulation FD Disclosure
18 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Regulation FD Disclosure
5 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
Transcripts
PCSA
Earnings call transcript
2022 Q4
30 Mar 23
PCSA
Earnings call transcript
2022 Q3
13 Nov 22
PCSA
Earnings call transcript
2022 Q2
14 Aug 22
PCSA
Earnings call transcript
2022 Q1
14 May 22
PCSA
Earnings call transcript
2021 Q4
31 Mar 22
PCSA
Earnings call transcript
2021 Q3
12 Nov 21
PCSA
Earnings call transcript
2021 Q2
13 Aug 21
PCSA
Earnings call transcript
2021 Q1
14 May 21
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 8.68 mm | 8.68 mm | 8.68 mm | 8.68 mm | 8.68 mm | 8.68 mm |
| Cash burn (monthly) | 688.16 k | 282.25 k | 904.82 k | 2.16 mm | 688.16 k | 804.19 k |
| Cash used (since last report) | 1.87 mm | 768.13 k | 2.46 mm | 5.88 mm | 1.87 mm | 2.19 mm |
| Cash remaining | 6.80 mm | 7.91 mm | 6.21 mm | 2.79 mm | 6.80 mm | 6.49 mm |
| Runway (months of cash) | 9.9 | 28.0 | 6.9 | 1.3 | 9.9 | 8.1 |
Institutional ownership, Q2 2023
55.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 21 |
| Opened positions | 4 |
| Closed positions | 7 |
| Increased positions | 2 |
| Reduced positions | 6 |
| 13F shares | Current |
|---|---|
| Total value | 702.98 mm |
| Total shares | 13.72 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| David Young | 11.44 mm | $45.20 mm |
| Yuhan (usa) | 750.00 k | $2.96 mm |
| Walleye Capital | 366.64 k | $182.40 mm |
| Vanguard | 361.68 k | $179.94 mm |
| Citadel Advisors | 282.84 k | $140.71 mm |
| Manchester Management | 142.43 k | $819.00 k |
| Geode Capital Management | 68.83 k | $34.24 mm |
| Coastal Bridge Advisors | 52.50 k | $26.26 mm |
| Renaissance Technologies | 45.40 k | $23.00 k |
| STT State Street | 42.79 k | $21.29 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 8 Aug 23 | George K Ng | RSU Common Stock | Grant | Acquire A | No | No | 0 | 400,000 | 0.00 | 800,000 |
| 8 Aug 23 | George K Ng | RSU Common Stock | Grant | Acquire A | No | No | 0 | 400,000 | 0.00 | 400,000 |
| 27 Jun 23 | Geraldine Pannu | Common Stock | Option exercise | Acquire M | No | No | 0 | 23,636 | 0.00 | 53,113 |
| 27 Jun 23 | Geraldine Pannu | Restricted Stock Common Stock | Grant | Acquire A | No | No | 0 | 101,365 | 0.00 | 101,365 |
| 27 Jun 23 | Geraldine Pannu | Restricted Stock Common Stock | Option exercise | Dispose M | No | No | 0 | 23,636 | 0.00 | 0 |
| 27 Jun 23 | Baluch Khoso | Common Stock | Option exercise | Acquire M | No | No | 0 | 15,455 | 0.00 | 27,955 |
| 27 Jun 23 | Baluch Khoso | Restricted Stock Common Stock | Grant | Acquire A | No | No | 0 | 101,365 | 0.00 | 101,365 |
| 27 Jun 23 | Baluch Khoso | Restricted Stock Common Stock | Option exercise | Dispose M | No | No | 0 | 15,455 | 0.00 | 0 |
| 27 Jun 23 | Virgil Thompson | Common Stock | Option exercise | Acquire M | Yes | No | 0 | 23,636 | 0.00 | 123,849 |
| 27 Jun 23 | Virgil Thompson | Restricted Stock Common Stock | Grant | Acquire A | No | No | 0 | 101,365 | 0.00 | 101,365 |
News
Why Nikola Shares Are Trading Higher By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
18 Sep 23
Why Rubicon Technologies Shares Are Trading Lower By Over 7%; Here Are 20 Stocks Moving Premarket
18 Sep 23
12 Health Care Stocks Moving In Friday's After-Market Session
15 Sep 23
Stocks That Hit 52-Week Lows On Monday
11 Sep 23
Stocks That Hit 52-Week Lows On Wednesday
6 Sep 23
Press releases
Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
6 Sep 23
Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care
17 Aug 23
Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference
10 Aug 23
Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer
8 Aug 23